Incyte Jak1 inhibitors were not confirmed in GVHD trials
-
Last Update: 2021-03-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Incyte announced the latest results from its Phase II study, which evaluated Itacitinib (formerly incb039110) in a combined treatment with corticosteroids to treat patients who had not received acute graft anti-host disease (gvhd).The company revealed that the drug combination did not reach the main endpoint of improving the overall mitigation rate compared to placebo - data for 74.0% vs. 66.4%.Ultimately, the drug improved the overall remission rate in patients with untreated acute GVHD. However, the difference with placebo corticosteroids was not statistically significant.Nor did we observe non-relapse mortality differences between the six-month treatment group and the placebo group, which was a key secondary endpoint of the study.Steven Stein, the company's chief medical officer, called the results "disappointing." He continued: "However, we remain committed to the success of the Ruxotinib research program, which has shown positive results in the incurable acute GVHD of steroids.“ In addition, we will continue to study the role of jak inhibition in chronic GVHD and preventive environments as we seek to develop treatments for patients with this debilitating and fatal disease. After , Incyte will inform the researchers of the results and work with them to properly conclude the study in a manner that is in the best interests of each patient.The company also announced that the data for the study will be presented at an upcoming scientific conference. （cyy123.com）
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
